468 related articles for article (PubMed ID: 2911205)
1. Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol.
Berman E; Arlin ZA; Gaynor J; Miller W; Gee T; Kempin SJ; Mertelsmann R; Andreeff M; Reich L; Nahmias N
Leukemia; 1989 Feb; 3(2):115-21. PubMed ID: 2911205
[TBL] [Abstract][Full Text] [Related]
2. Amsacrine, cytarabine and thioguanine (AAT) versus daunorubicin, cytarabine, thioguanine (DAT) in adults with untreated acute non-lymphoblastic leukemia (ANLL). Austrian-German results.
Linkesch W; Michlmayr G; Gerhartz H; Illinger H; König H; Düllmann J; Keilhauer R; Moldrzyk D
Onkologie; 1989 Feb; 12(1):8-10. PubMed ID: 2654791
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up of a randomized post-induction therapy trial in acute myelogenous leukemia (a Southeastern Cancer Study Group trial).
Volger WR; Weiner RS; Moore JO; Omura GA; Bartolucci AA; Stagg M
Leukemia; 1995 Sep; 9(9):1456-60. PubMed ID: 7544851
[TBL] [Abstract][Full Text] [Related]
4. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
Hansen OP; Pedersen-Bjergaard J; Ellegaard J; Brincker H; Boesen AM; Christensen BE; Drivsholm A; Hippe E; Jans H; Jensen KB
Leukemia; 1991 Jun; 5(6):510-6. PubMed ID: 2056774
[TBL] [Abstract][Full Text] [Related]
5. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A;
J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036
[TBL] [Abstract][Full Text] [Related]
6. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group.
Arlin Z; Case DC; Moore J; Wiernik P; Feldman E; Saletan S; Desai P; Sia L; Cartwright K
Leukemia; 1990 Mar; 4(3):177-83. PubMed ID: 2179638
[TBL] [Abstract][Full Text] [Related]
7. Influence of daunorubicin and cytarabine sequencing on the outcome of therapy in acute myelogenous leukemia: a randomized trial.
Archimbaud E; Fiere D; Treille-Ritouet D; Adeleine P; Guyotat D; Sebban C; Vuvan H; Viala JJ
Cancer Treat Rep; 1987 Jun; 71(6):571-4. PubMed ID: 3555788
[TBL] [Abstract][Full Text] [Related]
8. Oral induction and consolidation of acute myeloid leukemia with etoposide, 6-thioguanine, and idarubicin (ETI) in elderly patients: a randomized comparison with 5-day TAD. Finnish Leukemia Group.
Ruutu T; Almqvist A; Hallman H; Honkanen T; Järvenpää E; Järventie G; Koistinen P; Koivunen E; Lahtinen R; Lehtinen M
Leukemia; 1994 Jan; 8(1):11-5. PubMed ID: 8289475
[TBL] [Abstract][Full Text] [Related]
9. [Intensification chemotherapy followed by allogenieic and autologous bone marrow transplantation in acute non-lymphoblastic leukemia in children].
Ortega Aramburu JJ; Olivé Oliveras T; Javier Manchón G; Bastida Vila P; Sánchez C; Giralt López J
Sangre (Barc); 1991 Feb; 36(1):7-14. PubMed ID: 1853274
[TBL] [Abstract][Full Text] [Related]
10. [A regimen of DATV in the treatment of acute nonlymphocytic leukemia with high complete remission rate].
Lou FD; Zhou Q; Meng FY
Zhonghua Nei Ke Za Zhi; 1992 Mar; 31(3):146-8, 187. PubMed ID: 1395925
[TBL] [Abstract][Full Text] [Related]
11. A randomized trial of induction therapy (daunorubicin, vincristine, prednisone versus daunorubicin, vincristine, prednisone, cytarabine and 6-thioguanine) in adult acute lymphoblastic leukemia with long-term follow-up: an Eastern Cooperative Oncology Group Study (E3486).
Wiernik PH; Cassileth PA; Leong T; Hoagland HC; Bennett JM; Paietta E; Oken MM;
Leuk Lymphoma; 2003 Sep; 44(9):1515-21. PubMed ID: 14565653
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of recurrence of acute myeloid leukemia in childhood. A retrospective analysis of recurrence in the AML-BFM-83 study].
Stahnke K; Ritter J; Schellong G; Beck JD; Kabisch H; Lampert F; Creutzig U
Klin Padiatr; 1992; 204(4):253-7. PubMed ID: 1518261
[TBL] [Abstract][Full Text] [Related]
13. Therapy of acute myelogenous leukemia in patients over the age of 50: a randomized Southeastern Cancer Study Group trial.
Stein RS; Vogler WR; Winton EF; Cohen HJ; Raney MR; Bartolucci A
Leuk Res; 1990; 14(10):895-903. PubMed ID: 2259226
[TBL] [Abstract][Full Text] [Related]
14. A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75.
Reiffers J; Huguet F; Stoppa AM; Molina L; Marit G; Attal M; Gastaut JA; Michallet M; Lepeu G; Broustet A; Pris J; Maraninchi D; Hollard D; Fabères C; Mercier M; Hurteloup P; Danel P; Tellier Z; Berthaud P
Leukemia; 1996 Mar; 10(3):389-95. PubMed ID: 8642852
[TBL] [Abstract][Full Text] [Related]
15. High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial.
Schaich M; Parmentier S; Kramer M; Illmer T; Stölzel F; Röllig C; Thiede C; Hänel M; Schäfer-Eckart K; Aulitzky W; Einsele H; Ho AD; Serve H; Berdel WE; Mayer J; Schmitz N; Krause SW; Neubauer A; Baldus CD; Schetelig J; Bornhäuser M; Ehninger G
J Clin Oncol; 2013 Jun; 31(17):2094-102. PubMed ID: 23630210
[TBL] [Abstract][Full Text] [Related]
16. High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: an update.
Wolff SN; Herzig RH; Phillips GL; Lazarus HM; Greer JP; Stein RS; Ray WA; Herzig GP
Semin Oncol; 1987 Jun; 14(2 Suppl 1):12-7. PubMed ID: 3589687
[TBL] [Abstract][Full Text] [Related]
17. Randomized study of individualized induction therapy with or without VCR, and of maintenance of 4 or 12 courses in adult AML: JALSG-AML87. Japan Adult Leukemia Study Group (JALSG).
Ohno R; Kobayashi T; Morishima Y; Hiraoka A; Imai K; Asoh N; Tsubaki K; Tomonaga M; Takahashi I; Kodera K
Leukemia; 1992; 6 Suppl 2():92-5. PubMed ID: 1578954
[TBL] [Abstract][Full Text] [Related]
18. [A late phase II comparative study of idarubicin + cytarabine and daunorubicin + cytarabine in adult patients with acute non-lymphocytic leukemia. Idarubicin Study Group].
Masaoka T; Ogawa M; Yamada K; Kimura K; Ohhashi Y
Gan To Kagaku Ryoho; 1993 Oct; 20(13):1995-2005. PubMed ID: 8215474
[TBL] [Abstract][Full Text] [Related]
19. Remission-induction regimens in acute nonlymphocytic leukemia.
Brennan DC; Lewis JP
West J Med; 1980 Oct; 133(4):279-88. PubMed ID: 7347042
[TBL] [Abstract][Full Text] [Related]
20. Etoposide in the management of leukemia: a review.
Bishop JF
Semin Oncol; 1991 Feb; 18(1 Suppl 2):62-9. PubMed ID: 1992536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
